{ "version": "https://jsonfeed.org/version/1.1", "title": "Drugnews｜Taiwan Biotech Intelligence", "home_page_url": "https://drugnews.com.tw/en/", "feed_url": "https://drugnews.com.tw/en/feed.json", "description": "Independent biotech and pharmaceutical intelligence from Taiwan, covering clinical data, company strategy, licensing, valuation, and capital markets.", "language": "en", "items": [ { "id": "https://drugnews.com.tw/articles/2026-07-17-revmed-ras-en.html", "url": "https://drugnews.com.tw/articles/2026-07-17-revmed-ras-en.html", "title": "RevMed Upends Pancreatic Cancer Again: The RAS Combination Era Has Arrived", "content_text": "Daraxonrasib has already raised the bar with phase 3 overall-survival data. Early zoldonrasib combinations now suggest that pancreatic cancer's RAS competition is shifting from single agents to treatment ecosystems.", "date_published": "2026-07-17T09:46:13+08:00", "tags": [ "Business Analysis", "Revolution Medicines", "RevMed", "pancreatic cancer", "KRAS G12D", "RAS(ON)", "zoldonrasib", "daraxonrasib", "ESMO GI 2026", "clinical data", "combination therapy", "oncology" ] }, { "id": "https://drugnews.com.tw/en/guides/regulatory-milestones.html", "url": "https://drugnews.com.tw/en/guides/regulatory-milestones.html", "title": "How to read FDA regulatory milestones: what each event changes—and what it does not", "content_text": "A practical guide to INDs, FDA designations, pivotal alignment, NDA/BLA review, PDUFA dates, advisory committees, complete response letters, and approval pathways.", "date_published": "2026-07-17T09:00:00+08:00", "tags": [ "Research Guides", "Regulatory Milestones" ] }, { "id": "https://drugnews.com.tw/en/guides/bd-licensing-terms.html", "url": "https://drugnews.com.tw/en/guides/bd-licensing-terms.html", "title": "How to read biotech licensing deals: from headline value to risk-adjusted economics", "content_text": "A practical guide to biotech licensing terms: upfront cash, milestones, royalties, territory, control, development obligations, supply, termination, and risk-adjusted deal economics.", "date_published": "2026-07-17T09:00:00+08:00", "tags": [ "Research Guides", "BD and Licensing Terms" ] }, { "id": "https://drugnews.com.tw/en/guides/clinical-endpoints.html", "url": "https://drugnews.com.tw/en/guides/clinical-endpoints.html", "title": "How to read biotech clinical endpoints without overreading a positive headline", "content_text": "A practical guide to primary endpoints, effect size, confidence intervals, multiplicity, surrogate endpoints, and the questions that keep a positive biotech readout from being overread.", "date_published": "2026-07-17T09:00:00+08:00", "tags": [ "Research Guides", "Clinical Endpoints" ] }, { "id": "https://drugnews.com.tw/articles/2026-07-16-big-pharma-ma-new-aesthetic-en.html", "url": "https://drugnews.com.tw/articles/2026-07-16-big-pharma-ma-new-aesthetic-en.html", "title": "Big Pharma's New $10 Billion M&A Wave: Why Differentiation Now Beats Scale and Hype", "content_text": "Vertex's roughly $10 billion deal for Crinetics captures a wider change in Big Pharma's acquisition taste: away from scale and fashionable platforms, toward niche leadership, technological step-changes and commercial visibility.", "date_published": "2026-07-16T08:00:00+08:00", "tags": [ "Business Analysis", "Big Pharma", "biotech M&A", "Vertex", "Crinetics", "AbbVie", "Apogee Therapeutics", "Novartis", "Avidity Biosciences", "Merck", "Cidara Therapeutics", "BD licensing", "Taiwan biotech" ] }, { "id": "https://drugnews.com.tw/articles/2026-07-15-treg-immune-tolerance-productization-en.html", "url": "https://drugnews.com.tw/articles/2026-07-15-treg-immune-tolerance-productization-en.html", "title": "After the Nobel Prize, Do Not Rush the First-Approved Treg Story: The Real Test Is Turning Immune Tolerance Into a Product", "content_text": "The Nobel Prize illuminated Treg biology, but commercial value will depend on whether immune tolerance can become a releasable, trackable, scalable and reimbursable product, not on an unverified first-approval headline.", "date_published": "2026-07-15T08:00:00+08:00", "tags": [ "Business Analysis", "regulatory T cells", "Treg", "immune tolerance", "cell therapy", "autoimmune disease", "transplantation", "CMC", "Taiwan Bio Therapeutics", "Taiwan biotech", "clinical development" ] }, { "id": "https://drugnews.com.tw/articles/2026-07-14-novartis-myricx-nmti-adc-en.html", "url": "https://drugnews.com.tw/articles/2026-07-14-novartis-myricx-nmti-adc-en.html", "title": "The Next ADC War: Novartis Is Paying Up to $1.5 Billion for Myricx, but the Real Prize Is a New Payload Class", "content_text": "Novartis is paying up to $1.5 billion for Myricx. The strategic prize is not merely two ADC assets, but an NMT-inhibitor payload platform that could reopen the questions of therapeutic window, resistance and platform value.", "date_published": "2026-07-14T08:00:00+08:00", "tags": [ "Business Analysis", "ADC", "Novartis", "Myricx Bio", "NMT inhibitor", "ADC payload", "BD licensing", "oncology", "Taiwan biotech", "biotech valuation", "drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-07-13-anthropic-claude-science-ai-drug-discovery-en.html", "url": "https://drugnews.com.tw/articles/2026-07-13-anthropic-claude-science-ai-drug-discovery-en.html", "title": "Foundation Models Enter Drug Discovery: Anthropic Launches Claude Science as AI Companies Move Into the Real R&D Arena", "content_text": "Anthropic's launch of Claude Science and its move into drug discovery show foundation-model companies shifting from research tools into real R&D workflows. AI drug discovery will ultimately be judged by experiments, clinical data and tradable assets.", "date_published": "2026-07-13T08:00:00+08:00", "tags": [ "Business Analysis", "AI drug discovery", "Claude Science", "Anthropic", "foundation models", "drug development", "AnHorn Medicines", "PROTAC", "CMC", "clinical assets", "biotech business analysis", "Taiwan biotech" ] }, { "id": "https://drugnews.com.tw/articles/2026-07-12-roche-divarasib-kras-generation-en.html", "url": "https://drugnews.com.tw/articles/2026-07-12-roche-divarasib-kras-generation-en.html", "title": "Winning First Is Not Winning: Roche's Divarasib Pushes KRAS Into a Generational Elimination Race", "content_text": "Roche's divarasib beat first-generation KRAS G12C inhibitors in a head-to-head Phase III study, moving the RAS field from proving druggability to replacing earlier products with harder clinical evidence.", "date_published": "2026-07-12T08:00:00+08:00", "tags": [ "Business Analysis", "KRAS G12C", "divarasib", "Roche", "oncology", "clinical data", "PFS", "OS", "biotech business analysis", "Taiwan biotech" ] }, { "id": "https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns-en.html", "url": "https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns-en.html", "title": "Fasedienol's Phase 3 Brake: The Story Did Not Fail. The CNS Evidence Bar Did Its Job.", "content_text": "Fasedienol's PALISADE-4 miss was not simply a failed Phase 3 headline. It exposed the core CNS drug-development problem: a beautiful mechanism and a real unmet need still have to survive subjective endpoints, placebo response, patient selection, and a commercial repositioning test.", "date_published": "2026-07-11T09:49:00+08:00", "tags": [ "Business Analysis", "Free Article", "biotech business analysis", "Taiwan biotech", "drug development", "CNS drug development", "social anxiety disorder", "fasedienol", "PALISADE-4", "Vistagen", "clinical data", "biotech valuation", "clinical endpoints", "biotech investing" ] }, { "id": "https://drugnews.com.tw/articles/2026-07-10-fda-nasp-en.html", "url": "https://drugnews.com.tw/articles/2026-07-10-fda-nasp-en.html", "title": "Sobi's NASP Received an FDA CRL: The Problem Was Manufacturing Credibility, Not Efficacy", "content_text": "FDA identified no clinical efficacy or safety concerns that affected NASP's approvability. The setback centered on CMC controls and contract-manufacturing deficiencies, showing biotech investors why manufacturing credibility becomes part of asset value near launch.", "date_published": "2026-07-10T09:49:00+08:00", "tags": [ "Business Analysis", "Free Article", "biotech business analysis", "Taiwan biotech", "drug development", "FDA CRL", "NASP", "Sobi", "CMC", "contract manufacturing", "manufacturing quality", "uncontrolled gout", "URAT1", "clinical data", "biotech investing" ] }, { "id": "https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap-en.html", "url": "https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap-en.html", "title": "Why Has Japan Struggled to Build Global-Scale Biotech Companies?", "content_text": "Japan has strong science, major pharmaceutical companies, and a large drug market. The harder question is why that foundation has not produced more global-scale biotech startups. The answer is not scientific weakness, but an ecosystem gap across assets, talent, capital, clinical execution, and exits.", "date_published": "2026-07-09T09:30:00+08:00", "tags": [ "Business Analysis", "Free Article", "biotech business analysis", "Japan biotech", "Taiwan biotech", "startup ecosystem", "drug development", "clinical data", "CMC", "BD licensing", "biotech valuation", "capital markets", "big pharma" ] }, { "id": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "content_text": "GLP-1 competition is moving from peak weight loss toward long-term use, tolerability, rebound control, and combination design. Dorzagliatin matters not as a GLP-1 replacement, but as a possible metabolic base for the next phase of chronic therapy.", "date_published": "2026-07-08T09:10:35+08:00", "tags": [ "Business Analysis", "Free Article", "biotech business analysis", "Taiwan biotech", "GLP-1", "dorzagliatin", "glucokinase activator", "GKA", "drug development", "metabolic disease", "type 2 diabetes", "MASH", "clinical data", "BD licensing", "biotech valuation", "API / CDMO", "capital markets" ] }, { "id": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html", "title": "Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot", "content_text": "After a Phase III setback for sigvotatug vedotin, Pfizer's $43 billion Seagen ADC bet is increasingly tied to whether 3SBio's PD-1/VEGF bispecific can become a new immuno-oncology combination backbone.", "date_published": "2026-07-07T08:49:37+08:00", "tags": [ "Business Analysis", "Free Article", "biotech business analysis", "Taiwan biotech", "ADC", "PD-1/VEGF", "bispecific antibody", "oncology", "BD licensing", "clinical data", "drug development", "biotech valuation", "Big Pharma" ] }, { "id": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html", "title": "Off-the-Shelf CAR-T in 2026: Rebounding From the Trough", "content_text": "Off-the-shelf allogeneic CAR-T is no longer just a beautiful manufacturing story. In 2026, better clinical signals and clearer positioning are bringing the field back to the table.", "date_published": "2026-07-06T12:26:18+08:00", "tags": [ "Business Analysis", "Free Article", "biotech business analysis", "Taiwan biotech", "cell therapy", "CAR-T", "allogeneic cell therapy", "clinical data", "drug development", "autoimmune disease", "biotech valuation" ] }, { "id": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html", "title": "Big Pharma's $134 Billion M&A Rush: What Is It Really Buying?", "content_text": "In the first half of 2026, Big Pharma's biotech M&A pace has accelerated sharply. The real question is not why large drugmakers have cash, but why they are suddenly less willing to wait.", "date_published": "2026-07-05T12:10:13+08:00", "tags": [ "Business Analysis", "Free Article", "biotech business analysis", "Taiwan biotech", "BD licensing", "biotech M&A", "biotech valuation", "clinical data", "drug development", "capital markets", "Big Pharma" ] }, { "id": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html", "title": "Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition", "content_text": "Operation TrialBlazer is not just an FDA efficiency program. It signals that the United States is treating clinical-trial speed as part of national biotech competitiveness, with direct implications for biotech valuation, financing windows, and regulatory strategy.", "date_published": "2026-07-04T08:35:00+08:00", "tags": [ "HHS", "FDA", "Operation TrialBlazer", "clinical trial reform", "biotech business analysis", "Taiwan biotech", "drug development", "clinical data", "BD licensing", "biotech valuation", "regulatory policy", "capital markets" ] }, { "id": "https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.html", "url": "https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.html", "title": "RevMed Says No to Being Bought: Biotech's Independent Era", "content_text": "Revolution Medicines is choosing not to make a sale its priority. The decision reflects a broader shift: top-tier biotech companies with breakthrough assets may once again have a credible path to grow into independent biopharma companies.", "date_published": "2026-07-03T10:30:00+08:00", "tags": [ "Revolution Medicines", "RevMed", "daraxonrasib", "RAS oncology", "biotech business analysis", "Taiwan biotech", "BD licensing", "biotech valuation", "clinical data", "capital markets" ] }, { "id": "https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.html", "url": "https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.html", "title": "Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find", "content_text": "PARP inhibitors turned synthetic lethality into a commercial reality. Two decades later, the industry is still asking why the next PARP-like blockbuster has been so difficult to reproduce.", "date_published": "2026-07-02T10:30:00+08:00", "tags": [ "synthetic lethality", "PARP", "PRMT5", "MTAP", "RAS", "oncology", "biomarkers", "Taiwan biotech", "drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.html", "url": "https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.html", "title": "Centanafadine’s Phase 3b Win: Why ADHD Treatment Is Moving Beyond Discipline and Toward Neurobiology", "content_text": "Otsuka’s centanafadine has reported positive Phase 3b data in adults with ADHD and comorbid anxiety. The FDA has accepted the NDA and granted priority review, making the program a useful lens for how ADHD treatment is shifting from behavioral stigma toward more precise neurobiological intervention.", "date_published": "2026-07-01T10:30:00+08:00", "tags": [ "ADHD", "centanafadine", "Otsuka", "clinical data", "neuroscience", "non-stimulant ADHD therapy", "Taiwan biotech", "drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html", "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html", "title": "GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy", "content_text": "GSK's $10.6 billion all-cash acquisition of Nuvalent is more than a late-stage lung-cancer pipeline deal. It is a strategic attempt to rebuild oncology, buy time before major revenue pressure, and regain a seat at the precision-oncology table.", "date_published": "2026-06-30T00:43:58.356Z", "tags": [ "GSK", "Nuvalent", "Oncology", "Lung cancer", "ROS1", "ALK", "BD", "M&A", "Biotech investing", "Big Pharma" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-29-biotech-ipo-en.html", "url": "https://drugnews.com.tw/articles/2026-06-29-biotech-ipo-en.html", "title": "The Largest Biotech IPO in US Market History: What Parabilis Is Really Teaching Investors", "content_text": "Parabilis Medicines' record-setting US biotech IPO is not a sign that speculative biotech is back. It shows that investors are willing to fund high-risk innovation when the platform, clinical asset, external validation, and capital-market window all line up.", "date_published": "2026-06-29T05:50:47.700Z", "tags": [ "Biotech IPO", "Parabilis Medicines", "Helicons", "Zolucatetide", "Wnt beta-catenin", "Regeneron", "Biotech investing", "Capital markets" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html", "url": "https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html", "title": "The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer", "content_text": "Biotech’s recent rebound is not only a risk-on trade. FDA review signals, rare-disease flexibility, mRNA vaccine momentum, and renewed pharma M&A are changing how investors price clinical-stage assets.", "date_published": "2026-06-28T08:50:00+08:00", "tags": [ "FDA", "Biotech rebound", "Regulatory risk", "Rare disease", "Gene therapy", "mRNA vaccines", "M&A", "Capital markets" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html", "url": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html", "title": "Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside", "content_text": "Pancreatic cancer is moving into a new phase of precision combination therapy, as RAS inhibition meets MTAP-selective PRMT5 and MAT2A strategies.", "date_published": "2026-06-27T10:30:00+08:00", "tags": [ "Pancreatic Cancer", "RAS", "PRMT5", "MAT2A", "Synthetic Lethality", "Clinical Data", "Biotech Investing", "BD" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html", "url": "https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html", "title": "Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path?", "content_text": "Lilly is testing whether tirzepatide can move beyond weight loss and become part of an immunometabolism strategy for chronic immune-inflammatory diseases.", "date_published": "2026-06-26T10:30:00+08:00", "tags": [ "GLP-1", "tirzepatide", "Zepbound", "Taltz", "Omvoh", "immunometabolism", "autoimmune disease", "psoriasis", "IBD", "Eli Lilly", "biotech investing" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform-en.html", "url": "https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform-en.html", "title": "Toward the “Roche of Pet Medicine”: Protect Biotech’s Platform Bet", "content_text": "As companion animals age and owners become more willing to pay for serious-disease care, the next major question in pet medicine is whether a platform company can connect drugs, diagnostics, veterinary clinics, regulation, manufacturing, channels, and data into one defensible system.", "date_published": "2026-06-25T08:30:00+08:00", "tags": [ "Business Analysis", "Protect Biotech", "Companion Animal Medicine", "Pet Precision Medicine", "Platform Company", "Biotech Investing", "Roche", "Animal Health" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html", "url": "https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html", "title": "Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head", "content_text": "Takeda's zasocitinib beat Sotyktu in a head-to-head Phase 3 psoriasis study, turning AI-enabled drug design into a real commercial test.", "date_published": "2026-06-24T08:13:00+08:00", "tags": [ "AI drug discovery", "zasocitinib", "Takeda", "Sotyktu", "TYK2", "psoriasis", "PASI 100", "Schrodinger", "biotech investing", "Big Pharma" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html", "url": "https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html", "title": "The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk?", "content_text": "Lilly and Novo Nordisk dominate the first phase of the obesity-drug market. The next investment question is who can become the third major player by solving the problems GLP-1 leaders have not fully solved.", "date_published": "2026-06-22T08:49:01+08:00", "tags": [ "Obesity medicine", "GLP-1", "Eli Lilly", "Novo Nordisk", "Pfizer", "Roche", "AstraZeneca", "Regeneron", "Biotech investing", "Capital markets" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda-en.html", "url": "https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda-en.html", "title": "Merck's Shift on PD-1/VEGF Bispecifics: Keytruda Still Rules, but the Next IO Backbone Is Getting Closer", "content_text": "Merck's more serious positioning of MK-2010 suggests that PD-1/VEGF bispecifics are moving from a watch item to a strategic option in the post-Keytruda oncology landscape.", "date_published": "2026-06-21T08:00:00+08:00", "tags": [ "Merck", "Keytruda", "PD-1 VEGF", "MK-2010", "Oncology", "Bispecific antibodies" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury-en.html", "url": "https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury-en.html", "title": "Enlivex's RAIN Token Windfall: When a Biotech Balance Sheet Starts Looking Like Crypto Treasury Strategy", "content_text": "Enlivex's paper gain from RAIN tokens shows how fragile biotech business models can create unusual treasury stories when operating revenue is absent and capital markets are difficult.", "date_published": "2026-06-20T08:00:00+08:00", "tags": [ "Enlivex", "RAIN token", "Biotech treasury", "Crypto", "Capital markets" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en.html", "url": "https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en.html", "title": "GSK's US$10.6 Billion Nuvalent Deal Is Really a Bet on Resistance and Brain Metastases", "content_text": "GSK is not merely buying three lung-cancer pipelines. It is buying a next-generation precision-oncology strategy around resistance, CNS activity, and cleaner kinase inhibition.", "date_published": "2026-06-19T08:00:00+08:00", "tags": [ "GSK", "Nuvalent", "Lung cancer", "Precision oncology", "Resistance", "Brain metastases" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html", "url": "https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html", "title": "Ecnoglutide Versus Wegovy: A 20-Week Head-to-Head Signal Is Not the Same as a New GLP-1 King", "content_text": "Ecnoglutide's head-to-head weight-loss data versus semaglutide are interesting, but the GLP-1 race will be decided by long-term outcomes, tolerability, labels, supply, and global evidence.", "date_published": "2026-06-17T09:30:00+08:00", "tags": [ "GLP-1", "Ecnoglutide", "Wegovy", "Pfizer", "Novo Nordisk", "Obesity medicine" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine-en.html", "url": "https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine-en.html", "title": "Why Would Lilly, the Obesity-Drug Giant, Spend US$3.8 Billion on Vaccine Companies?", "content_text": "Lilly's vaccine acquisitions show that the company is using obesity-drug cash flow to widen its long-term disease-prevention and immunology strategy.", "date_published": "2026-06-16T11:00:00+08:00", "tags": [ "Eli Lilly", "Vaccines", "M&A", "Prevention medicine", "Obesity medicine" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t-en.html", "url": "https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t-en.html", "title": "ASCO 2026: RAS, ADCs, Bispecifics, and In Vivo CAR-T Point to a New Oncology Cycle", "content_text": "ASCO 2026 showed that oncology is moving from single-mechanism breakthroughs toward platform combinations across RAS targeting, ADCs, PD-1/VEGF bispecifics, and in vivo CAR-T.", "date_published": "2026-06-15T10:35:00+08:00", "tags": [ "ASCO", "Oncology", "RAS", "ADC", "PD-1 VEGF", "In vivo CAR-T" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-14-revolution-medicines-en.html", "url": "https://drugnews.com.tw/articles/2026-06-14-revolution-medicines-en.html", "title": "Revolution Medicines: Why Biotech Winners Need Capital Strategy, Not Just Good Science", "content_text": "Revolution Medicines shows why next-generation biotech companies need to convert clinical momentum into capital momentum if they want to finish expensive global drug-development races.", "date_published": "2026-06-14T00:54:00.739Z", "tags": [ "RAS", "Revolution Medicines", "Daraxonrasib", "Biotech financing", "Pancreatic cancer", "Capital markets" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-13-anhorn-ai-drug-development-en.html", "url": "https://drugnews.com.tw/articles/2026-06-13-anhorn-ai-drug-development-en.html", "title": "The Next Phase of AI Drug Development: Making Molecules Survive as Drugs", "content_text": "AI drug development is moving from molecular generation to clinical survival. AnHorn Medicines shows how AI+PROTAC, experimental feedback, and human translation may form a Taiwan-born clinical-asset engine.", "date_published": "2026-06-13T15:20:00+08:00", "tags": [ "AI Drug Development", "AnHorn Medicines", "AI+PROTAC", "AIMCADD", "NVIDIA", "Clinical Asset Engine", "Biotech" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612-en.html", "url": "https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612-en.html", "title": "Where Does AI Drug Discovery Stand Now? A Pipeline-Based Reality Check", "content_text": "AI drug discovery has moved beyond the concept stage and into clinical validation. This article reviews Zasocitinib, GB-0895, Zovegalisib, and REC-4881 to examine how different AI strategies are being converted into real drug assets.", "date_published": "2026-06-12T10:30:00+08:00", "tags": [ "AI drug discovery", "Clinical pipelines", "Biotech investing", "Business development", "Drug development", "Big Pharma" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle-en.html", "url": "https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle-en.html", "title": "Obesity Becomes King: How GLP-1 Is Reshuffling Global Biotech Capital", "content_text": "GLP-1 is no longer only a weight-loss topic. It is redirecting biotech capital, BD urgency, manufacturing attention, and valuation imagination across global pharma.", "date_published": "2026-06-11T08:00:01+08:00", "tags": [ "Biotech Valuation", "Obesity medicine", "Business development", "Capital markets", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer-en.html", "url": "https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer-en.html", "title": "RAS Targeting Opens a New Pancreatic-Cancer Window: How Senhwa's CX-5461 Positions for the Next Resistance-Management War", "content_text": "Daraxonrasib opens a new pancreatic-cancer window, but the next value question is resistance management. Senhwa's CX-5461 matters if it can become a rational combination partner.", "date_published": "2026-06-10T10:45:00+08:00", "tags": [ "Company Research", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story-en.html", "url": "https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story-en.html", "title": "Biotech IR Is Not Making Slides Prettier; It Is Turning Pipelines Into Trackable Capital-Market Stories", "content_text": "Biotech IR is not cosmetic storytelling. Good IR turns clinical, CMC, regulatory, commercial, and financing milestones into a capital-market narrative that investors can actually track.", "date_published": "2026-06-10T10:30:00+08:00", "tags": [ "IR and Capital Markets", "Capital markets", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition-en.html", "url": "https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition-en.html", "title": "The US$7 Billion Radiopharma Deal Rumor: Curium Wants Lantheus, but the Real Prize Is a Ticket to the Nuclear-Medicine Era", "content_text": "Curium's rumored interest in Lantheus is best read as a bid for nuclear-medicine infrastructure: isotope access, hospital channels, imaging workflow, and radiopharma commercialization depth.", "date_published": "2026-06-09T10:30:00+08:00", "tags": [ "BD and Licensing", "Radiopharma", "Business development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era-en.html", "url": "https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era-en.html", "title": "CAR-T Enters a New Era: From Blood Cancer to Autoimmune Disease", "content_text": "CAR-T's move from blood cancer into autoimmune disease could redefine cell therapy, but the value depends on whether deep immune reset can justify manufacturing complexity, safety risk, and cost.", "date_published": "2026-06-08T10:30:00+08:00", "tags": [ "Clinical and CMC", "CAR-T", "Regulatory risk", "Immunology", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future-en.html", "url": "https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future-en.html", "title": "Drugmakers Without AI Capability May No Longer Be Called Drugmakers", "content_text": "AI is becoming a core operating capability for pharma, but its value comes from improving discovery, translation, trial design, and portfolio decisions rather than from marketing language alone.", "date_published": "2026-06-07T10:30:00+08:00", "tags": [ "IR and Capital Markets", "AI drug discovery", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy-en.html", "url": "https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy-en.html", "title": "Old Targets Are Crowded, but They Can Still Make Money", "content_text": "Crowded drug targets can still create value when companies differentiate through patient selection, formulation, route of administration, clinical design, pricing, or commercial channel strategy.", "date_published": "2026-06-06T10:30:00+08:00", "tags": [ "BD and Licensing", "Business development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery-en.html", "url": "https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery-en.html", "title": "Starting With Ruxolitinib Cream: Why Not Every JAK Molecule Can Become a Topical Drug", "content_text": "Topical JAK drugs are not won by target biology alone. The real value lies in skin delivery, local exposure, systemic safety, indication choice, and whether the product can fit daily dermatology practice.", "date_published": "2026-06-05T10:30:00+08:00", "tags": [ "Clinical and CMC", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss-en.html", "url": "https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss-en.html", "title": "Retatrutide Moves Toward Surgery-Level Weight Loss: Lilly's Triple-Agonist Pushes Obesity Treatment Into a New Arena", "content_text": "Retatrutide pushes obesity-drug efficacy toward surgery-level territory, but the real competitive battle will be durability, tolerability, body composition, comorbidity benefit, and access.", "date_published": "2026-06-04T10:30:00+08:00", "tags": [ "Company Research", "Obesity medicine", "Big Pharma", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing-en.html", "url": "https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing-en.html", "title": "A Genetic Disease With No New Treatment for 40 Years Finally Enters a New Drug Era", "content_text": "AATD is entering a new treatment cycle after decades of limited options, with RNA and gene-based approaches trying to move the field beyond symptom control and protein replacement.", "date_published": "2026-06-03T10:30:00+08:00", "tags": [ "Clinical and CMC", "Immunology", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy-en.html", "url": "https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy-en.html", "title": "Biogen's High-Risk Bet: Can Tau Find a Way Out of the Alzheimer's R&D Graveyard?", "content_text": "Biogen's BIIB080 tau program reflects a broader Alzheimer's reset: the field is no longer only asking whether amyloid matters, but whether tau biology can produce measurable disease-modifying benefit.", "date_published": "2026-06-02T10:30:00+08:00", "tags": [ "Clinical and CMC", "CNS", "Big Pharma", "Capital markets", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth-en.html", "url": "https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth-en.html", "title": "Pluvicto Is Selling Fast: What Radioligand Therapy Growth Really Means", "content_text": "Pluvicto's rapid growth shows radioligand therapy moving from specialist science into a real commercial infrastructure story, where isotope supply, hospital workflow, and patient selection become strategic assets.", "date_published": "2026-06-01T10:30:00+08:00", "tags": [ "Company Research", "Radiopharma", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis-en.html", "url": "https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis-en.html", "title": "The Tavneos Crisis: Death Reports, Data-Integrity Questions, and an Amgen Rare-Disease Star at the Edge of Withdrawal", "content_text": "A Drugnews English brief on The Tavneos Crisis: Death Reports, Data-Integrity Questions, and an Amgen Rare-Disease Star at the Edge of Withdrawal, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-31T10:30:00+08:00", "tags": [ "Clinical and CMC", "Regulatory risk", "Immunology", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling-en.html", "url": "https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling-en.html", "title": "The Best Partner for a Drug King? When Combination Therapy Doubles Efficacy", "content_text": "A Drugnews English brief on The Best Partner for a Drug King? When Combination Therapy Doubles Efficacy, focusing on company strategy, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-30T10:30:00+08:00", "tags": [ "Clinical and CMC", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-29-next-generation-obesity-therapy-directions-en.html", "url": "https://drugnews.com.tw/articles/2026-05-29-next-generation-obesity-therapy-directions-en.html", "title": "Weight-Loss Drugs Are No Longer Only About Body Weight: Where Next-Generation Therapies Are Aiming", "content_text": "A Drugnews English brief on Weight-Loss Drugs Are No Longer Only About Body Weight: Where Next-Generation Therapies Are Aiming, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-29T10:30:00+08:00", "tags": [ "Clinical and CMC", "AI drug discovery", "Obesity medicine", "Capital markets", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-28-biotech-investment-judgment-system-en.html", "url": "https://drugnews.com.tw/articles/2026-05-28-biotech-investment-judgment-system-en.html", "title": "Biotech Investing Needs a Judgment System, Not More News", "content_text": "A Drugnews English brief on Biotech Investing Needs a Judgment System, Not More News, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-28T10:30:00+08:00", "tags": [ "Business Analysis", "Business development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework-en.html", "url": "https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework-en.html", "title": "The First Step in Valuing Taiwanese Biotech: Stop Forcing Every Company Into the Same P/E Ratio", "content_text": "A Drugnews English brief on The First Step in Valuing Taiwanese Biotech: Stop Forcing Every Company Into the Same P/E Ratio, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-27T10:30:00+08:00", "tags": [ "Biotech Valuation", "AI drug discovery", "Capital markets", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety-en.html", "url": "https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety-en.html", "title": "Sun Pharma, Teva, and the Transformation Anxiety of Global Generic Drugmakers", "content_text": "A Drugnews English brief on Sun Pharma, Teva, and the Transformation Anxiety of Global Generic Drugmakers, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-27T10:30:00+08:00", "tags": [ "Company Research", "Big Pharma", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-26-weight-loss-side-effect-new-track-en.html", "url": "https://drugnews.com.tw/articles/2026-05-26-weight-loss-side-effect-new-track-en.html", "title": "A New Weight-Loss Drug Side Effect Accidentally Opens a New Therapeutic Track", "content_text": "A Drugnews English brief on A New Weight-Loss Drug Side Effect Accidentally Opens a New Therapeutic Track, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-26T10:30:00+08:00", "tags": [ "Clinical and CMC", "Obesity medicine", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets-en.html", "url": "https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets-en.html", "title": "Asthma Drugs Are Shifting Gears: From Triple Inhalers to Upstream Immune Targets", "content_text": "A Drugnews English brief on Asthma Drugs Are Shifting Gears: From Triple Inhalers to Upstream Immune Targets, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-25T10:30:00+08:00", "tags": [ "Clinical and CMC", "Immunology", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity-en.html", "url": "https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity-en.html", "title": "Why OX2R Is Heating Up: From Narcolepsy to the Next CNS Drug Opportunity", "content_text": "A Drugnews English brief on Why OX2R Is Heating Up: From Narcolepsy to the Next CNS Drug Opportunity, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-24T10:30:00+08:00", "tags": [ "Business Analysis", "Obesity medicine", "CNS", "Regulatory risk", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend-en.html", "url": "https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend-en.html", "title": "The Global Biotech Wave: Understanding the Main Phase and Scientific Pricing of the Five-Trillion Weight-Loss Market", "content_text": "A Drugnews English brief on The Global Biotech Wave: Understanding the Main Phase and Scientific Pricing of the Five-Trillion Weight-Loss Market, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-23T10:30:00+08:00", "tags": [ "Business Analysis", "AI drug discovery", "Obesity medicine", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow-en.html", "url": "https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow-en.html", "title": "How Mid-Sized Biotechs Are Turning Blockbuster Drugs From Dreams Into Cash Flow", "content_text": "A Drugnews English brief on How Mid-Sized Biotechs Are Turning Blockbuster Drugs From Dreams Into Cash Flow, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-22T10:30:00+08:00", "tags": [ "Business Analysis", "Obesity medicine", "CNS", "Regulatory risk", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-21-ai-semiconductor-biotech-capital-neglect-en.html", "url": "https://drugnews.com.tw/articles/2026-05-21-ai-semiconductor-biotech-capital-neglect-en.html", "title": "How AI Semiconductors Have Hidden the Biotech Opportunity in Plain Sight", "content_text": "A Drugnews English brief on How AI Semiconductors Have Hidden the Biotech Opportunity in Plain Sight, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-21T10:30:00+08:00", "tags": [ "Business Analysis", "AI drug discovery", "Regulatory risk", "Business development", "Capital markets", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-20-ai-drug-discovery-google-funding-en.html", "url": "https://drugnews.com.tw/articles/2026-05-20-ai-drug-discovery-google-funding-en.html", "title": "A Record AI Drug-Discovery Financing: Why a Google-Backed Company Raised US$2.1 Billion", "content_text": "A Drugnews English brief on A Record AI Drug-Discovery Financing: Why a Google-Backed Company Raised US$2.1 Billion, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-20T10:30:00+08:00", "tags": [ "Company Research", "AI drug discovery", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth-en.html", "url": "https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth-en.html", "title": "HIV Drugs Are Still Highly Profitable: What Gilead's Earnings Reveal", "content_text": "A Drugnews English brief on HIV Drugs Are Still Highly Profitable: What Gilead's Earnings Reveal, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-19T10:30:00+08:00", "tags": [ "Business Analysis", "CAR-T", "Targeted therapy", "Regulatory risk", "Big Pharma", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake-en.html", "url": "https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake-en.html", "title": "Where Pfizer Misjudged the Vepdegestrant Strategy", "content_text": "A Drugnews English brief on Where Pfizer Misjudged the Vepdegestrant Strategy, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-18T10:30:00+08:00", "tags": [ "Business Analysis", "Targeted therapy", "Regulatory risk", "Big Pharma", "Business development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge-en.html", "url": "https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge-en.html", "title": "Johnson & Johnson Cuts Two Autologous Lymphoma CAR-T Programs", "content_text": "A Drugnews English brief on Johnson & Johnson Cuts Two Autologous Lymphoma CAR-T Programs, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-17T10:30:00+08:00", "tags": [ "Business Analysis", "CAR-T", "Targeted therapy", "Regulatory risk", "Big Pharma", "Business development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson-en.html", "url": "https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson-en.html", "title": "Daiichi Sankyo's Most Expensive Lesson: How an ADC Capacity Bet Can Backfire After a Blockbuster", "content_text": "A Drugnews English brief on Daiichi Sankyo's Most Expensive Lesson: How an ADC Capacity Bet Can Backfire After a Blockbuster, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-17T10:30:00+08:00", "tags": [ "Clinical and CMC", "AI drug discovery", "Targeted therapy", "Big Pharma", "Capital markets", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk-en.html", "url": "https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk-en.html", "title": "The FDA Commissioner's Exit: Why the World's Most Important Drug Referee Is Becoming Less Predictable", "content_text": "A Drugnews English brief on The FDA Commissioner's Exit: Why the World's Most Important Drug Referee Is Becoming Less Predictable, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-16T10:30:00+08:00", "tags": [ "Business Analysis", "Regulatory risk", "Business development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline-en.html", "url": "https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline-en.html", "title": "A Complete Map of the New Antidepressant Drug Pipeline", "content_text": "A Drugnews English brief on A Complete Map of the New Antidepressant Drug Pipeline, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-15T10:30:00+08:00", "tags": [ "Business Analysis", "Obesity medicine", "CNS", "Regulatory risk", "Business development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation-en.html", "url": "https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation-en.html", "title": "How PharmaEssentia's Besremi Opens a Larger Valuation Imagination", "content_text": "A Drugnews English brief on How PharmaEssentia's Besremi Opens a Larger Valuation Imagination, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-14T10:30:00+08:00", "tags": [ "Business Analysis", "Targeted therapy", "Regulatory risk", "Capital markets", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback-en.html", "url": "https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback-en.html", "title": "Could Neuroinflammation Bring CNS Drug Development Back?", "content_text": "A Drugnews English brief on Could Neuroinflammation Bring CNS Drug Development Back?, focusing on cns, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-13T10:30:00+08:00", "tags": [ "Business Analysis", "CNS", "Big Pharma", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-12-jnj-autoimmune-twins-stelara-transition-en.html", "url": "https://drugnews.com.tw/articles/2026-05-12-jnj-autoimmune-twins-stelara-transition-en.html", "title": "The Autoimmune Twins That Could Save Johnson & Johnson", "content_text": "A Drugnews English brief on The Autoimmune Twins That Could Save Johnson & Johnson, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-12T10:30:00+08:00", "tags": [ "Business Analysis", "CAR-T", "Regulatory risk", "Big Pharma", "Business development", "Immunology", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy-en.html", "url": "https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy-en.html", "title": "Could DAC Become the Next Breakout Format in Targeted Therapy?", "content_text": "A Drugnews English brief on Could DAC Become the Next Breakout Format in Targeted Therapy?, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-11T10:30:00+08:00", "tags": [ "Business Analysis", "Targeted therapy", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-10-glp1-medicare-policy-delay-en.html", "url": "https://drugnews.com.tw/articles/2026-05-10-glp1-medicare-policy-delay-en.html", "title": "Trump Delays the Policy Signal: Did Weight-Loss Drugs Cut Prices for Nothing?", "content_text": "A Drugnews English brief on Trump Delays the Policy Signal: Did Weight-Loss Drugs Cut Prices for Nothing?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-10T10:30:00+08:00", "tags": [ "Business Analysis", "Obesity medicine", "CNS", "Regulatory risk", "Capital markets", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-09-clinical-trial-fraud-fda-withdrawal-en.html", "url": "https://drugnews.com.tw/articles/2026-05-09-clinical-trial-fraud-fda-withdrawal-en.html", "title": "Clinical-Trial Fraud and an FDA Withdrawal Storm", "content_text": "A Drugnews English brief on Clinical-Trial Fraud and an FDA Withdrawal Storm, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-09T10:30:00+08:00", "tags": [ "Clinical and CMC", "Regulatory risk", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth-en.html", "url": "https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth-en.html", "title": "Weight-Loss Drugs Are Still Too Strong: Lilly's Mounjaro Keeps Printing Money", "content_text": "A Drugnews English brief on Weight-Loss Drugs Are Still Too Strong: Lilly's Mounjaro Keeps Printing Money, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-08T10:30:00+08:00", "tags": [ "Business Analysis", "Obesity medicine", "CAR-T", "Targeted therapy", "CNS", "Big Pharma", "Capital markets", "Biotech business analysis" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war-en.html", "url": "https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war-en.html", "title": "The Shadow Behind the Next Century-Defining Drug", "content_text": "A Drugnews English brief on The Shadow Behind the Next Century-Defining Drug, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-07T10:30:00+08:00", "tags": [ "Business Analysis", "CAR-T", "Targeted therapy", "CNS", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop-en.html", "url": "https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop-en.html", "title": "Free Taipei Workshop: Using an NPV Framework to Identify Biotech Re-Rating Points", "content_text": "A Drugnews English brief on Free Taipei Workshop: Using an NPV Framework to Identify Biotech Re-Rating Points, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-06T10:30:00+08:00", "tags": [ "Business Analysis", "AI drug discovery", "Capital markets", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction-en.html", "url": "https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction-en.html", "title": "What Makes a Pipeline Attractive to Big Pharma?", "content_text": "A Drugnews English brief on What Makes a Pipeline Attractive to Big Pharma?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-05T10:30:00+08:00", "tags": [ "Business Analysis", "Obesity medicine", "Targeted therapy", "CNS", "Regulatory risk", "Business development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-04-hair-growth-drug-breakthrough-en.html", "url": "https://drugnews.com.tw/articles/2026-05-04-hair-growth-drug-breakthrough-en.html", "title": "The Hair-Growth Drug That Jumped 47%: Why It Could Rewrite Three Decades of Hair-Loss Treatment", "content_text": "A Drugnews English brief on The Hair-Growth Drug That Jumped 47%: Why It Could Rewrite Three Decades of Hair-Loss Treatment, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-04T10:30:00+08:00", "tags": [ "Clinical and CMC", "AI drug discovery", "Capital markets", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly-en.html", "url": "https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly-en.html", "title": "In Vivo CAR-T: Bubble or the Most Expensive Ticket to Next-Generation Cell Therapy?", "content_text": "A Drugnews English brief on In Vivo CAR-T: Bubble or the Most Expensive Ticket to Next-Generation Cell Therapy?, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-03T10:30:00+08:00", "tags": [ "Business Analysis", "CAR-T", "Big Pharma", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-02-sun-pharma-organon-acquisition-en.html", "url": "https://drugnews.com.tw/articles/2026-05-02-sun-pharma-organon-acquisition-en.html", "title": "The Ambition of an Indian Pharma Giant: Acquiring a US Drugmaker", "content_text": "A Drugnews English brief on The Ambition of an Indian Pharma Giant: Acquiring a US Drugmaker, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-02T10:30:00+08:00", "tags": [ "Business Analysis", "Big Pharma", "Business development", "Capital markets", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse-en.html", "url": "https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse-en.html", "title": "Is the 20-Year Amyloid Hypothesis in Alzheimer's Disease Starting to Collapse?", "content_text": "A Drugnews English brief on Is the 20-Year Amyloid Hypothesis in Alzheimer's Disease Starting to Collapse?, focusing on cns, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-05-01T10:30:00+08:00", "tags": [ "Business Analysis", "CNS", "Regulatory risk", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-30-amazon-ai-nvidia-en.html", "url": "https://drugnews.com.tw/articles/2026-04-30-amazon-ai-nvidia-en.html", "title": "Amazon Enters AI Drug Discovery and Challenges Nvidia's Pharma Ambition", "content_text": "A Drugnews English brief on Amazon Enters AI Drug Discovery and Challenges Nvidia's Pharma Ambition, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-30T10:30:00+08:00", "tags": [ "Business Analysis", "AI drug discovery", "Business development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-29-dcard-261388300-en.html", "url": "https://drugnews.com.tw/articles/2026-04-29-dcard-261388300-en.html", "title": "A Clear Read on Lilly's Current M&A Logic", "content_text": "A Drugnews English brief on A Clear Read on Lilly's Current M&A Logic, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-29T10:30:00+08:00", "tags": [ "Business Analysis", "AI drug discovery", "Obesity medicine", "Big Pharma", "Business development", "Immunology", "Clinical development", "Biotech business analysis" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-28-dcard-261381952-en.html", "url": "https://drugnews.com.tw/articles/2026-04-28-dcard-261381952-en.html", "title": "When a Gray-Market Industry Gets a Seat at the Table", "content_text": "A Drugnews English brief on When a Gray-Market Industry Gets a Seat at the Table, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-28T10:30:00+08:00", "tags": [ "Business Analysis", "AI drug discovery", "Obesity medicine", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-27-car-t-en.html", "url": "https://drugnews.com.tw/articles/2026-04-27-car-t-en.html", "title": "Goodbye Autologous CAR-T: Why Taiwan's Cell-Therapy Bubble Also Needs to Break", "content_text": "A Drugnews English brief on Goodbye Autologous CAR-T: Why Taiwan's Cell-Therapy Bubble Also Needs to Break, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-27T10:30:00+08:00", "tags": [ "Business Analysis", "AI drug discovery", "CAR-T", "Immunology", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-26-dcard-261370593-en.html", "url": "https://drugnews.com.tw/articles/2026-04-26-dcard-261370593-en.html", "title": "The Healthcare-Giant Spin-Off Wave", "content_text": "A Drugnews English brief on The Healthcare-Giant Spin-Off Wave, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-26T10:30:00+08:00", "tags": [ "Business Analysis", "Business development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-25-biotech-5-en.html", "url": "https://drugnews.com.tw/articles/2026-04-25-biotech-5-en.html", "title": "Why Platform Biotechs Can Generate Five Times More Licensing Revenue", "content_text": "A Drugnews English brief on Why Platform Biotechs Can Generate Five Times More Licensing Revenue, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-25T10:30:00+08:00", "tags": [ "Business Analysis", "Business development", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-24-dcard-261359193-en.html", "url": "https://drugnews.com.tw/articles/2026-04-24-dcard-261359193-en.html", "title": "Investors Should Pay Attention: Drug Delivery Is a Blue Ocean", "content_text": "A Drugnews English brief on Investors Should Pay Attention: Drug Delivery Is a Blue Ocean, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-24T10:30:00+08:00", "tags": [ "Business Analysis", "Business development", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-23-dcard-261352566-en.html", "url": "https://drugnews.com.tw/articles/2026-04-23-dcard-261352566-en.html", "title": "Do COPD Patients Finally Have Another New Drug Option?", "content_text": "A Drugnews English brief on Do COPD Patients Finally Have Another New Drug Option?, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-23T10:30:00+08:00", "tags": [ "Business Analysis", "Business development", "Immunology", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-22-ai-en.html", "url": "https://drugnews.com.tw/articles/2026-04-22-ai-en.html", "title": "The Three AI Giants Battling Inside Medicine", "content_text": "A Drugnews English brief on The Three AI Giants Battling Inside Medicine, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-22T10:30:00+08:00", "tags": [ "Business Analysis", "AI drug discovery", "Business development", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-21-dcard-261339270-en.html", "url": "https://drugnews.com.tw/articles/2026-04-21-dcard-261339270-en.html", "title": "Did Lilly's Oral Drug Ignite the Market?", "content_text": "A Drugnews English brief on Did Lilly's Oral Drug Ignite the Market?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-21T10:30:00+08:00", "tags": [ "Business Analysis", "AI drug discovery", "Obesity medicine", "Big Pharma", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-20-dcard-261332702-en.html", "url": "https://drugnews.com.tw/articles/2026-04-20-dcard-261332702-en.html", "title": "A Historic Moment: The Next Century-Defining Drug Has Arrived", "content_text": "A Drugnews English brief on A Historic Moment: The Next Century-Defining Drug Has Arrived, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-20T10:30:00+08:00", "tags": [ "Business Analysis", "Obesity medicine", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-19-neuralink-10-en.html", "url": "https://drugnews.com.tw/articles/2026-04-19-neuralink-10-en.html", "title": "Neuralink and the Next Trillion-Dollar Race: Ten Brain-Computer Interface Companies to Know", "content_text": "A Drugnews English brief on Neuralink and the Next Trillion-Dollar Race: Ten Brain-Computer Interface Companies to Know, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-19T10:30:00+08:00", "tags": [ "Business Analysis", "AI drug discovery", "CNS", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-18-biotech-ai-en.html", "url": "https://drugnews.com.tw/articles/2026-04-18-biotech-ai-en.html", "title": "Could This Taiwanese Biotech Capture the Entire AI Infrastructure Dividend?", "content_text": "A Drugnews English brief on Could This Taiwanese Biotech Capture the Entire AI Infrastructure Dividend?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-18T10:30:00+08:00", "tags": [ "Business Analysis", "AI drug discovery", "Capital markets", "Immunology", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-17-dcard-261315054-en.html", "url": "https://drugnews.com.tw/articles/2026-04-17-dcard-261315054-en.html", "title": "The Valley of Death in Innovative Drug Development", "content_text": "A Drugnews English brief on The Valley of Death in Innovative Drug Development, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-17T10:30:00+08:00", "tags": [ "Business Analysis", "Business development", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-16-2026-q2-en.html", "url": "https://drugnews.com.tw/articles/2026-04-16-2026-q2-en.html", "title": "The 2026 Q2 Drug Catalysts Biotech Readers Need to Know", "content_text": "A Drugnews English brief on The 2026 Q2 Drug Catalysts Biotech Readers Need to Know, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-16T10:30:00+08:00", "tags": [ "Business Analysis", "Immunology", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-15-biotech-en.html", "url": "https://drugnews.com.tw/articles/2026-04-15-biotech-en.html", "title": "The Fall of Two Star Biotechs", "content_text": "A Drugnews English brief on The Fall of Two Star Biotechs, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-15T10:30:00+08:00", "tags": [ "Business Analysis", "Obesity medicine", "Business development", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-14-dcard-261295358-en.html", "url": "https://drugnews.com.tw/articles/2026-04-14-dcard-261295358-en.html", "title": "Investors Should Pay Attention to the Autoimmune Mega-Drug Race", "content_text": "A Drugnews English brief on Investors Should Pay Attention to the Autoimmune Mega-Drug Race, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-14T10:30:00+08:00", "tags": [ "Business Analysis", "Business development", "Immunology", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-13-78-en.html", "url": "https://drugnews.com.tw/articles/2026-04-13-78-en.html", "title": "The King of Weight-Loss Drugs: Did US$7.8 Billion Buy the Next Era of Metabolic Medicine?", "content_text": "A Drugnews English brief on The King of Weight-Loss Drugs: Did US$7.8 Billion Buy the Next Era of Metabolic Medicine?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-13T10:30:00+08:00", "tags": [ "Business Analysis", "AI drug discovery", "Obesity medicine", "Business development", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-12-dcard-261282303-en.html", "url": "https://drugnews.com.tw/articles/2026-04-12-dcard-261282303-en.html", "title": "Idiopathic Pulmonary Fibrosis Is Entering an Acceleration Phase", "content_text": "A Drugnews English brief on Idiopathic Pulmonary Fibrosis Is Entering an Acceleration Phase, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-12T10:30:00+08:00", "tags": [ "Business Analysis", "Immunology", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-11-dcard-261276232-en.html", "url": "https://drugnews.com.tw/articles/2026-04-11-dcard-261276232-en.html", "title": "Why Did the Market Like This Company More After a Clinical Failure?", "content_text": "A Drugnews English brief on Why Did the Market Like This Company More After a Clinical Failure?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-11T10:30:00+08:00", "tags": [ "Business Analysis", "AI drug discovery", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-10-dcard-261269760-en.html", "url": "https://drugnews.com.tw/articles/2026-04-10-dcard-261269760-en.html", "title": "When Should a Company Decisively Abandon a Clinical Trial?", "content_text": "A Drugnews English brief on When Should a Company Decisively Abandon a Clinical Trial?, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-10T10:30:00+08:00", "tags": [ "Business Analysis", "Business development", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-09-dcard-261263509-en.html", "url": "https://drugnews.com.tw/articles/2026-04-09-dcard-261263509-en.html", "title": "A New Drug Finally Arrives for This Group of Rare-Disease Patients", "content_text": "A Drugnews English brief on A New Drug Finally Arrives for This Group of Rare-Disease Patients, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-09T10:30:00+08:00", "tags": [ "Business Analysis", "AI drug discovery", "Immunology", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-08-abivax-14-en.html", "url": "https://drugnews.com.tw/articles/2026-04-08-abivax-14-en.html", "title": "The Abivax Story: How a European Biotech Became a 14-Fold Market Myth", "content_text": "A Drugnews English brief on The Abivax Story: How a European Biotech Became a 14-Fold Market Myth, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-08T10:30:00+08:00", "tags": [ "Business Analysis", "Business development", "Immunology", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-07-cdc-en.html", "url": "https://drugnews.com.tw/articles/2026-04-07-cdc-en.html", "title": "While the US CDC Was Still Looking for a Director", "content_text": "A Drugnews English brief on While the US CDC Was Still Looking for a Director, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-07T10:30:00+08:00", "tags": [ "Business Analysis", "Regulatory risk", "Capital markets", "Immunology", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-06-420-en.html", "url": "https://drugnews.com.tw/articles/2026-04-06-420-en.html", "title": "The Cut-Rate Weight-Loss Injection Has Arrived: What a NT$420 Monthly Price Really Means", "content_text": "A Drugnews English brief on The Cut-Rate Weight-Loss Injection Has Arrived: What a NT$420 Monthly Price Really Means, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-06T10:30:00+08:00", "tags": [ "Business Analysis", "Obesity medicine", "Business development", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-05-dcard-261238352-en.html", "url": "https://drugnews.com.tw/articles/2026-04-05-dcard-261238352-en.html", "title": "How Far Are We From a Real Anti-Aging Drug?", "content_text": "A Drugnews English brief on How Far Are We From a Real Anti-Aging Drug?, focusing on clinical development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-05T10:30:00+08:00", "tags": [ "Business Analysis", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-04-dcard-261232633-en.html", "url": "https://drugnews.com.tw/articles/2026-04-04-dcard-261232633-en.html", "title": "Did Weight-Loss Injections Backfire and Trigger Pancreatitis Risk?", "content_text": "A Drugnews English brief on Did Weight-Loss Injections Backfire and Trigger Pancreatitis Risk?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-04T10:30:00+08:00", "tags": [ "Business Analysis", "Obesity medicine", "Capital markets", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-03-dcard-261227197-en.html", "url": "https://drugnews.com.tw/articles/2026-04-03-dcard-261227197-en.html", "title": "After GLP-1 and Mounjaro, What Is Happening in Weight-Loss Drug R&D?", "content_text": "A Drugnews English brief on After GLP-1 and Mounjaro, What Is Happening in Weight-Loss Drug R&D?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-03T10:30:00+08:00", "tags": [ "Business Analysis", "Obesity medicine", "Business development", "Clinical development", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-02-dcard-261221419-en.html", "url": "https://drugnews.com.tw/articles/2026-04-02-dcard-261221419-en.html", "title": "Can Merck Build Another Oncology Empire?", "content_text": "A Drugnews English brief on Can Merck Build Another Oncology Empire?, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-02T10:30:00+08:00", "tags": [ "Business Analysis", "Big Pharma", "Capital markets", "Biotech business analysis", "Drug development" ] }, { "id": "https://drugnews.com.tw/articles/2026-04-01-dcard-261215001-en.html", "url": "https://drugnews.com.tw/articles/2026-04-01-dcard-261215001-en.html", "title": "Innovent's Globalization Train: Did Taiwan's Forward Therapeutics Get On Board?", "content_text": "A Drugnews English brief on Innovent's Globalization Train: Did Taiwan's Forward Therapeutics Get On Board?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "date_published": "2026-04-01T10:30:00+08:00", "tags": [ "Business Analysis", "AI drug discovery", "Business development", "Clinical development", "Biotech business analysis", "Drug development" ] } ] }